ASH 2022 | EPCORE NHL-1: health-related QoL in patients with R/R LBCL treated with subcutaneous epcoritamab
Tycel Phillips, MD, City of Hope, Duarte, CA, briefly comments on the results of the EPCORE NHL-1 study (NCT04663347), which assessed patient-reported outcomes (PROs) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) treated with subcutaneous epcoritamab. Overall, it was found that responding patients experienced an improvement in quality of life (QoL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Abbvie, AstraZeneca, Bayer, Beigene, BMS, Eli Lily, Epizyme, Genmab, Genentech, Gilead, Incyte, Pharmacyclics, Xencor; Research support from Abbvie, Bayer, BMS, Incyte.
